Overview

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Status:
Terminated
Trial end date:
2018-10-07
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Allopurinol
Antilymphocyte Serum
Bendamustine Hydrochloride
Fludarabine
Fludarabine phosphate
Lenalidomide
Rituximab
Thalidomide
Thymoglobulin
Vidarabine